Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Wright Reports
|
$449.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
NuSep Holdings Ltd Announces Spin Out Of PrIME Biologics
NuSep Holdings Ltd announced that it has resolved, subject to shareholder approval, to spin out its therapeutic plasma fractionation business, called PrIME Biologics. PrIME Biologics is using the Company's PrIME Technology in its therapeutics plasma manufacturing process. It is PrIME Biologic's goal to open up the Asian therapeutic plasma market and particularly the untapped Currently Unprocessable Plasma (CUP) market.
Latest Key Developments in Biotechnology
- Oramed Pharmaceuticals Inc Receives FDA Clearance To Initiate Oral Insulin Trials In U.S.
- Cordlife Group Ltd Announces Proposed Acquisition Of CS Cell Technologies Pte. Ltd, Cordlife Stem Cell Technology Limited And Certain Assets Of P.T. Cordlife Indonesia From Cordlife Limited
- Stemline Therapeutics Inc Prices $60 Million Public Offering Of Common Stock
- Ambit Biosciences Corp Announces Pricing Of Initial Public Offering
- Share this
- Link this
- Digg this
Follow Reuters